Back to discover

Protein / target

Protein kinase C theta type

Encoded byPRKCQQ04759Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Protein serine/threonine kinase

Strongest disease association

Asthma

Via encoding gene PRKCQ · Genetic evidence · score 0.86

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription…

View complete UniProt function annotation

Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates in the calcium-dependent NFATC1 and NFATC2 transactivation (PubMed:21964608). Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. May also play an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway leading to JUN activation, acts by phosphorylating the mediator STK39/SPAK and may not act through MAP kinases signaling. Plays a critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by participating in the regulation of reduced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilization. After costimulation of T-cells through CD28 can phosphorylate CBLB and is required for the ubiquitination and subsequent degradation of CBLB, which is a prerequisite for the activation of TCR. During T-cells differentiation, plays an important role in the development of T-helper 2 (Th2) cells following immune and inflammatory responses, and, in the development of inflammatory autoimmune diseases, is necessary for the activation of IL17-producing Th17 cells. May play a minor role in Th1 response. Upon TCR stimulation, mediates T-cell protective survival signal by phosphorylating BAD, thus protecting T-cells from BAD-induced apoptosis, and by up-regulating BCL-X(L)/BCL2L1 levels through NF-kappa-B and JUN pathways. In platelets, regulates signal transduction downstream of the ITGA2B, CD36/GP4, F2R/PAR1 and F2RL3/PAR4 receptors, playing a positive role in 'outside-in' signaling and granule secretion signal transduction. May relay signals from the activated ITGA2B receptor by regulating the uncoupling of WASP and WIPF1, thereby permitting the regulation of actin filament nucleation and branching activity of the Arp2/3 complex. May mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1, which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. Phosphorylates MSN (moesin) in the presence of phosphatidylglycerol or phosphatidylinositol. Phosphorylates PDPK1 at 'Ser-504' and 'Ser-532' and negatively regulates its ability to phosphorylate PKB/AKT1. Phosphorylates CCDC88A/GIV and inhibits its guanine nucleotide exchange factor activity (PubMed:23509302). Phosphorylates and activates LRRK1, which phosphorylates RAB proteins involved in intracellular trafficking (PubMed:36040231)

Subcellular location

CytoplasmCell membrane
Domains and Gene Ontology detail (31)

Domains & features

C2Protein kinaseAGC-kinase C-terminal

Gene Ontology

  • Ccentriolar satellite
  • Ccytosol
  • Cimmunological synapse
  • Cplasma membrane
  • FATP binding
  • Fdiacylglycerol-dependent, calcium-independent serine/threonine kinase activity
  • Fprotein kinase activity
  • Fprotein serine kinase activity
  • Fprotein serine/threonine kinase activity
  • Fzinc ion binding
  • Paxon guidance
  • Pcell chemotaxis

706 aa · 82 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOLipid & lipoprotein metabolismUniProtKinase signallingUniProt · GOImmune signallingUniProt · GOTranscriptional regulationUniProt · GOHaemostasisUniProt · GO
View supporting evidence

Cell migration

  • ·cell chemotaxis

Lipid & lipoprotein metabolism

  • ·Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-p…

Kinase signalling

  • ·Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-p…
  • ·diacylglycerol-dependent, calcium-independent serine/threonine kinase activity
  • ·protein kinase activity
  • ·protein serine kinase activity

Immune signalling

  • ·Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-p…
  • ·inflammatory response
  • ·negative regulation of T cell apoptotic process
  • ·positive regulation of interleukin-17 production

Transcriptional regulation

  • ·Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-p…
  • ·regulation of DNA-templated transcription

Haemostasis

  • ·Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-p…
  • ·regulation of platelet aggregation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 4 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Leukemia, Myeloid, Acute1 medicine
Mastocytosis1 medicine
Mastocytosis, Systemic1 medicine
Broader indication categories (1)
Neoplasms1 medicine

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

midostaurin
ApprovedInhibitor

Protein kinase C (PKC) inhibitor

Indicated for Leukemia, Myeloid, Acute, Mastocytosis, Mastocytosis, Systemic, Neoplasms

Acts on a complex — shared with PRKD3, PRKCI, PRKCA +7 more · 1 of 16 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PRKCQ

Gene-level evidence surfaced through the gene PRKCQthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Asthma
0.87Well supported

Genetic evidence dominant · Open Targets 0.53

Dermatitis, Atopic
0.81Well supported

Genetic evidence dominant · Open Targets 0.49

Rhinitis, Allergic
0.74Moderately supported

Genetic evidence dominant · Open Targets 0.45

Childhood onset asthma
0.74Moderately supported

Genetic evidence dominant · Open Targets 0.45

Respiratory Tract Diseases
0.73Moderately supported

Genetic evidence dominant · Open Targets 0.45

View evidence synthesis (5)
AsthmaWell supported
0.87
agreement 0.731.00
Genetic99%Literature1%

Open Targets aggregate 0.53 · 2 independent evidence families

Dermatitis, AtopicWell supported
0.81
agreement 0.680.93
Genetic99%Literature1%RNA expression0%

Open Targets aggregate 0.49 · 3 independent evidence families

Rhinitis, AllergicModerately supported
0.74
agreement 0.600.88
Genetic100%Literature0%

Open Targets aggregate 0.45 · 2 independent evidence families

Childhood onset asthmaModerately supported
0.74
agreement 0.620.86
Genetic100%

Open Targets aggregate 0.45 · 1 independent evidence family

Respiratory Tract DiseasesModerately supported
0.73
agreement 0.610.85
Genetic100%

Open Targets aggregate 0.45 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Leukemia, Myeloid, Acute0.54
Asthma0.53
Dermatitis, Atopic0.49
Rhinitis, Allergic0.45
Childhood onset asthma0.45
Respiratory Tract Diseases0.45

Drug development

5 compounds recorded · 1 approved · 4 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (5)
UCN-01Phase 2
MIDOSTAURINApproval
GSK-690693Phase 1
CEP-2563Phase 1
SOTRASTAURINPhase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (10)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Med-Quality PocketSM · Druggable FamilyAB · GO CC high confAB · UniProt loc med confPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

cardiac arrhythmiaLamore et al. (2017)

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

3

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2017-09-18

    Approval: Rydapt (EMA)

    ema · regulatory · ema · via midostaurin

  2. New publication2017-07-24
    Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.

    Leukemia · 2018 · 109 citations · Europe PMC · via midostaurin

  3. New publication2016-06-01
    Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

    The New England journal of medicine · 2016 · 371 citations · Europe PMC · via midostaurin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.